NCT02008123

Effect of Primidone on Platelet Responsiveness in Patients Determined to be Clopidogrel Resistant

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Dent Neuroscience Research Center · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether adding primidone will improve the metabolism of clopidogrel thereby increasing metabolite levels within the blood stream and platelet response to clopidogrel in patients who were previously found to lack adequate response to clopidogrel. This information could help overcome clopidogrel resistance in patients who are at risk for stroke or transient ischemic attack (TIA).

Conditions

• Clopidogrel Resistance
• Secondary Stroke Prevention

Interventions

Type	Name	Description
DRUG	Primidone	Primidone is an antiepileptic used for the management of generalized tonic-clonic seizures and for the management of complex partial seizures. One of primidone's active metabolite is phenobarbital, which is a potent cytochrome P450 inducer. In this study, primidone will be used to induce CYP 1A2 in order to provide more efficient metabolism of clopidogrel to its active form

Timeline

• Start date: 2013-08-01
• Primary completion: 2017-12-01
• First posted: 2013-12-11
• Last updated: 2016-08-03

Locations

1 site across 1 country: United States